Aspargo Labs’ business model is repeatable and applies our proprietary technology to the world’s most meaningful compounds and brands.
Current and near-term projects have strong IP protection through 2036, including Oral Suspension for Sildenafil (VIAGRA®) through 2036.
Multiple patents granted for future digitally connected drug delivery device.
Aspargo Labs has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) as part of the process to become a publicly traded company. This filing includes details about the company’s business, financials, and the proposed listing of our shares on the New York Stock Exchange.
You can view the filed S-1 registration statement on the SEC’s database HERE.
Stay informed with our latest updates:
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) — Aspargo Labs, Inc. (“Aspargo Labs” or the “Company”), a pharmaceutical company commercializing an oral suspension spray technology, today announced
Adds experienced public-company finance executive to advance Aspargo’s corporate, commercial, and capital markets strategies NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) – Aspargo Labs, Inc. (“Aspargo Labs” or
New York, April 15, 2025 — Aspargo Labs, Inc. (“Aspargo Labs” or the “Company”), a pharmaceutical and MedTech company focused on converting the world’s most
New York, April 7, 2025 — Aspargo Labs, Inc. (“Aspargo Labs” or the “Company”), a specialty pharmaceutical and MedTech company focused on converting the world’s most
Accomplished regulatory affairs veteran to lead company’s global regulatory strategy and drug product development New York, February 26, 2025 – Aspargo Labs, Inc. (“Aspargo Labs” or
NEW YORK, December 20, 2024 – Aspargo Labs, Inc. (“Aspargo Labs” or the “Company”), a specialty pharmacy and MedTech company focused on reformulating the world’s
A world-first oral spray that combats erectile dysfunction within roughly 10 minutes has launched in the UK.
In an advance that could significantly lighten the load for caretakers in the “sandwich generation” and reduce loneliness in elderly patients, Aspargo Labs Inc. developed
Michael Demurjian, CEO of Aspargo Labs, discusses with Pharmaceutical Executive how their proprietary technology transforms traditional oral medications into liquid doses, improving delivery, absorption, and
Empowered Patient Podcast host, Karen Jagoda, speaks with Michael Demurjian, CEO of Aspargo Labs, about their innovative suspension-based drug delivery system designed to enhance absorption,
CEO Michael Demurjian discusses the importance of reformulated liquid oral suspension drugs, while outlining plans to launch a smart device that connects patients and doctors.
Aspargo Labs (AAGO) has filed to go public via a direct offering. The New York-based company, known for its liquid drug formulations and delivery devices,